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Abstract
The World Health Organization recommends anthelminthic treatment for pregnant women after the first trimester in soil-
transmitted helminth (STH) endemic regions to prevent adverse maternal-fetal consequences. Although studies have shown
the high prevalence of infection in the Philippines, no research has evaluated deworming practices. We hypothesized that
pregnant women are not receiving deworming treatment and we aimed to identify barriers to World Health Organization
guideline implementation. We conducted key informant interviews with local Department of Health (DOH) administrators,
focus group discussions with nurses, midwives, and health care workers, and knowledge, attitudes, and practices surveys
with women of reproductive age to elicit perspectives about deworming during pregnancy. Key informant interviews
revealed that healthcare workers were not deworming pregnant women due to inadequate drug supply, infrastructure and
personnel as well as fear of teratogenicity. Focus group discussions showed that healthcare workers similarly had not
implemented guidelines due to infrastructure challenges and concerns for fetal malformations. The majority of local women
believed that STH treatment causes side effects (74.8%) as well as maternal harm (67.3%) and fetal harm (77.9%). Women
who were willing to take anthelminthics while pregnant had significantly greater knowledge as demonstrated by higher
Treatment Scores (mean rank 146.92 versus 103.1, z =24.40, p,0.001) and higher Birth Defect Scores (mean rank 128.09
versus 108.65, z =22.43, p = 0.015). This study concludes that World Health Organization guidelines are not being
implemented in the Philippines. Infrastructure, specific protocols, and education for providers and patients regarding
anthelminthic treatment are necessary for the successful prevention of STH morbidity and mortality among pregnant
women.
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Introduction
Soil-transmitted helminth (STH) infections, caused by Ascaris,
Trichuris, and hookworms, are among the most prevalent neglected
tropical diseases and are a leading cause of malnutrition in the
developing world [1]. The World Health Organization (WHO)
developed specific guidelines for pregnant women due to increased
risk of comorbidities with STH infections. Helminth infection
contributes to anemia in females of childbearing age and is
associated with adverse maternal-fetal consequences including
premature birth, low birth weight, and decreased breast milk
production [2]. Current WHO guidelines for endemic regions
indicate treatment for all adolescent females and pregnant women
during the second and third trimester. A single dose of albendazole
400 mg or mebendazole 500 mg is recommended during the
second trimester. In highly endemic regions, a second dose is
recommended during the third trimester [3].
Many regions of the Philippines meet WHO criteria for
endemicity for STH infections. A 2012 survey showed an overall
prevalence of 30.4% (12.5%–61.8%) in adolescent females and
31.5% (13.2%–75.8%) in pregnant women. Of these infections,
7.9% (0.7%–22.6%) and 10.2% (0.9%–39.6%) were classified as
heavy intensity infections, respectively [4]. Furthermore, a 2005
study showed that 55% of pregnant women in the Philippines were
anemic [5].
The Philippines DOH published the Integrated Helminth
Control Program (IHCP) Strategic Plan for 2006–2010. The plan
outlined mass treatment strategies including biannual mass
targeted deworming for all children younger than 12 years of
age and annual selective deworming in endemic regions for special
groups upon presentation to a health clinic. These high risk groups
include adolescent females, pregnant women in the second or third
trimester, soldiers, farmers, food handlers, and indigenous people
[6,7].
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Despite the high prevalence of STH and anemia in Filipino
women, there are no studies that assess the implementation of
WHO guidelines for the pregnant population in the Philippines.
Multiple studies in Uganda, Sierra Leone, and Peru confirmed
that the use of anthelmintic medications during pregnancy
decreased the prevalence of STH infections [8,9,10,11]. A 2001
study in Sierra Leone showed that albendazole treatment during
pregnancy successfully reduced the prevalence of maternal anemia
[9].
Despite the efficacy of anthelmintic therapy during pregnancy,
the Philippine DOH has faced challenges in implementing mass
drug administration (MDA). The IHCP Strategic Plan described
obstacles within healthcare agencies such as non-compliance, poor
coverage of target populations, lack of sustainability and low
prioritization of the STH program relative to other DOH
initiatives such as vaccinations. Additional obstacles identified
include poor access to clean water and sanitation as well as low
acceptance among the targeted population [6]. The WHO
indicated financial constraints, limited drug access, and lack of
drug safety research as barriers to MDA in Western Pacific
countries [5]. Low levels of awareness and knowledge among
Filipinos were significantly associated with decreased acceptance
of MDA programs [12]. Past initiatives have identified challenges
to MDA, however, perspectives of providers and patients are
needed to develop a successful deworming program for women of
reproductive age.
The Philippines DOH is structured into national, regional, and
local divisions designed to implement national health programs.
The national STH coordinator oversees the distribution of
medication, funding, and national guidelines. Regional STH
coordinators work to provide communication between the local
and national division in the DOH in order to improve effectiveness
of health programs and respond to new challenges. The municipal
health officers are local physicians hired by the DOH to
implement national program at public health clinics termed Local
Health Units (LHUs) [13].
In this study we surveyed healthcare providers and patients to
determine current deworming practices and to identify potential
barriers for treating pregnant women. We hypothesized that this
population is not currently receiving anthelminthics and we aimed
to identify major barriers to treatment.
Methods
Study Sites
This study was conducted in June and July of 2011 in local
health units (LHUs) of two regions of the Philippines: Baguio City
and Cavite. The barangays, local government districts, in Baguio
City included Asin and Irisan. In Cavite the selected municipalities
were Dasmarin˜as and Tanza. An interview with the National STH
Coordinator was conducted at the DOH in Manila, Philippines
(Figure 1).
Figure 1. Study sites and participants. Key informant interviews were conducted with the National STH Coordinator, the Regional STH
Coordinator and four local municipal health officers from Baguio City and Cavite. Focus group discussions with nurses, midwives, and barangay
healthcare workers were conducted at each of the local health units along with Knowledge, Attitudes, and Practices surveys of women of
reproductive age.
doi:10.1371/journal.pone.0085992.g001
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Study Design
Key informant interviews (KIIs) were conducted with the DOH
National STH coordinator, the Baguio regional STH coordinator,
three local municipal health officers (MHOs) from Baguio, and
four MHOs from Cavite. The KIIs elicited perspectives of
government leaders regarding the prioritization and implementa-
tion of healthcare practices. In both Baguio and Cavite two Focus
group discussions (FGDs) were conducted with nurses, midwives,
and barangay health workers (BHWs) (Figure 1). The FGDs aimed
to identify the local understanding of STH infection and treatment
feasibility. Participants in the KIIs and FGDs were chosen based
on their ongoing collaboration with the University of Philippines-
Manila and NIH deworming initiative.
A cross-sectional Knowledge, Attitudes, and Practices (KAP)
survey was administered to 226 voluntary participants ages 18 to
45 years old who presented for care at the local health clinics in
Baguio City (n = 123) and Cavite (n = 103). Knowledge questions
addressed women’s understanding of modes of infection, treatment
methods, and potential maternal or fetal harm from medications.
Attitudes questions assessed willingness to take deworming
medication while pregnant. Practice questions evaluated previous
use of medications during pregnancy.
The English KAP survey was translated to Filipino and then
back-translated to English to ensure consistency in cultural
understanding of the survey tool. The survey was administered
in either language based on participant preference. The KAP
survey assessed local women’s understanding of STH infections
and their willingness to receive treatment.
Table 1. STH Treatment for Pregnant Women: Perspectives of Health Care Providers.
WHO Guideline Awareness and
Implementation Challenges Recommendations
National STH Coordinator Aware of WHO guidelines Fear of teratogenicity among
providers and patients
Prioritize deworming pregnant
women with positive stool samples
Excess drug supply Poor infrastructure Improve drug supply and communication
for local health units
50% coverage of pregnant women
is reasonable target
Regional STH Coordinator Aware of WHO guidelines Fear of teratogenicity among
providers and patients
Include deworming guidelines in
a DOH administrative order
Lack of local compliance Financial constraints in rural clinics Publish an updated STH manual
Expand the Maternal Newborn Child
and Nutrition (MANCHAN) program to
include deworming for pregnant women
Educate and train health workers
Municipal Health Officers Deworming pregnant women is not a
priority
Fear of maternal-fetal consequences
from medication
Provide evidence for deworming
necessity and safety
Detailed protocols and training
are lacking
Insufficient drug safety evidence Deworm at health clinics rather than
home visits
Pregnant women lack motivation
to seek care
Provide a sustainable drug supply
Non-cooperation of private physicians Educate women
Insufficient workforce
Poor drug supply
Nurses, Midwives, Barangay
Health Workers
Deworming medications are not given
to pregnant women
Transportation and financial
challenges of home visits
Train health workers
Pregnant women with positive stool
analyses are referred to physicians
Poor drug supply Deworm at health clinics rather than
home visits
Deworming medications are teratogenic Educate women
The National STH Coordinator, Regional STH Coordinator, and municipal health officers (MHOs) provided their perspectives during key informant interviews (KIIs).
Nurses, midwives, and barangay health workers provided data during focus group discussions (FGDs).
doi:10.1371/journal.pone.0085992.t001
Table 2. Characteristics of KAP survey participants.
Characteristics of Women of Reproductive Age
Age, mean6SD 28.768.65
Married 46.9%
High School Education or Higher 44.2%
Employed 24.8%
Public or Private Health Insurance 27.9%
Currently Pregnant 25.2%
Previous Pregnancies, mean6SD 2.462.5
Household Size, mean6SD 4.862.4
Rooms in home, mean6SD 2.061.3
A total of 226 women of reproductive age completed a Knowledge, Attitudes,
and Practices survey regarding STH infections during pregnancy. The majority
of women surveyed were between the ages of 20–37 years old, unemployed,
and did not complete a high school education.
doi:10.1371/journal.pone.0085992.t002
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Ethical Considerations
This study received ethical approval from the University of
Pittsburgh (PRO11030539) and the University of the Philippines –
Manila (NIH 2011-023). Written informed consent was obtained
from all study participants. The authors of this manuscript have
given written informed consent (as outlined in the PLOS consent
form) to publish these case details.
Data Processing and Analysis
KII and FGD recordings were analyzed using the Grounded
Theory approach [14]. This process involved analysis of audio files
from two coders who independently elicited themes from the
transcripts. The themes were compared and revised in order to
ensure the reliability of the final results. For the KAP responses,
frequency with percent distribution or mean with standard
deviation was determined. The Mann-Whitney U test was used
to correlate patients’ knowledge of STH to their attitudes
regarding treatment. A participant’s knowledge level was deter-
mined by three scores including Infection Score, Treatment Score
and Birth Defect Score with 32, 16, and 8 questions respectively.
Scores were based on the sums of correct responses in each subject
area. For the Infection Score, participants had to choose correct
answers in response to questions of prevention, transmission,
symptoms, and adverse effects with a maximum score of 32. For
instance, if a woman identified abdominal pain as a symptom of
infection, then she received one point. The Treatment Score was
based on knowledge of therapies. For example, selecting meben-
dazole as an effective treatment was worth one point, and selecting
papaya seeds as an ineffective treatment was also worth one point.
A greater Birth Defect Score indicated that a participant thought
deworming medications carried low risk of teratogenicity. For
instance a woman received one point if she responded ‘‘no’’ to the
question, ‘‘Will deworming medication cause physical deformity in
your baby?’’. The chi squared test (x2) was used to correlate
perceptions of side effects with attitudes regarding STH treat-
ments. The comparison groups were divided into those with
positive responses versus negative responses. Negative responses
included ‘‘no,’’ ‘‘unsure,’’ or no response. All statistical analysis
and data management were completed using SPSS Statistics 20.
Results
Key Informant Interviews
The national STH coordinator reported an abundant drug
supply at the central DOH office, but described infrastructure
challenges to drug delivery, especially in remote islands. She
advocated for better communication between national and local
leadership in order to distribute the available medications. The
national coordinator was aware that the WHO guidelines to
deworm pregnant women after the first trimester were not being
implemented, so she thought it was feasible to aim for an initial
goal of deworming 50% of the pregnant population. She stated the
fear of teratogenicity among physicians was a greater barrier to
STH treatment than fear among patients. She recommended
prioritizing deworming pregnant women with positive stool
samples and supplying drugs directly to LHUs.
The regional STH coordinator in Baguio City was also aware of
WHO guidelines for deworming during pregnancy and cited
patients’ fear of teratogenicity as the primary barrier to deworming
implementation. Due to patient concern and LHU non-compliance,
the regional coordinator recommended incorporating deworming
protocols into DOH guidelines for pregnant women and educating
patients and providers (Table 1).
The MHOs stated that insufficient evidence for albendazole/
mebendazole safety during pregnancy and the lack of specific
DOH protocols were the main barriers to STH treatment. In
addition, they believed that the independent practice of non-
government physicians, patients’ lack of motivation to seek
Table 3. Soil-transmitted helminth (STH) knowledge score, by willingness to take deworming medication while pregnant.
Knowledge Score
Willing to take deworming
medication while pregnant
Mean Rank (n=54)
Unwilling to take deworming
medication while pregnant
Mean Rank (n =172) z-value p-value
Modes of Infection 121.15 111.10 20.987 0.324
Treatment Methods 146.92 103.01 24.40 ,0.001
Potential Birth Defects 128.98 108.65 22.43 0.015
The Mann-Whitney U Test was used to compare the mean knowledge scale scores to the ‘‘yes/no’’ responses to the question, ‘‘Would you be willing to take deworming
medication while pregnant?’’ The 54 women who were willing to take deworming medications while pregnant had a greater knowledge of treatment methods and
potential birth defects than the 172 women who were not willing to take deworming medications while pregnant.
doi:10.1371/journal.pone.0085992.t003
Table 4. Soil-transmitted helminth (STH) knowledge scores, by willingness to participate in a government deworming program.
Knowledge Score
Willing to participate in a
government sponsored deworming
program Mean Rank (n=149)
Unwilling to participate in a
government sponsored deworming
program Mean Rank (n =77) z-value p-value
Modes of Infection 120.58 99.79 22.27 0.023
Treatment Methods 124.32 92.56 23.54 ,0.001
Potential Birth Defects 118.05 104.70 21.78 0.076
The Mann-Whitney U Test was used to compare the mean knowledge scale scores to the ‘‘yes/no’’ responses to the question, ‘‘Would you be willing to participate in a
government-sponsored deworming program?’’ The 149 women who were willing to participate in a government sponsored deworming program had a higher
knowledge of treatment methods and modes of infection than the 77 women who were not willing to participate in a government program.
doi:10.1371/journal.pone.0085992.t004
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prenatal care, and challenges of home visits were barriers to MDA.
Local providers felt that the DOH emphasized deworming and
vaccination programs for children above STH treatment for
pregnant women. They believed that low prioritization led to
insufficient drug supply, workforce, and education.
To implement deworming programs, MHOs primarily request-
ed drug safety evidence. One MHO said, ‘‘I attended a conference
where deworming pregnant women was mentioned but not
recommended because of concern for its side effects.’’ MHOs
wanted education and training programs. Finally, they requested
protocols for STH treatment in clinics rather than home visits, a
sustainable drug supply, and education for their female patients.
Focus Group Discussions
Nurses and midwives were either unaware or apprehensive
regarding treatment of STH during pregnancy. In Cavite, a nurse
said, ‘‘Deworming is not allowed for pregnant women,’’ and noted
that she would refer a pregnant woman to a physician if she had a
positive fecal analysis for STH infection. . In accordance with the
views of MHOs, nurses and midwives in Baguio City said they
were ‘‘anxious’’ about the uncertainty of teratogenic effects from
deworming medications (Table 1).
Healthcare workers described many barriers to implementing
WHO guidelines for STH treatment during pregnancy. Home
visits have commonly been used for prenatal care and have been
theorized as a potential vehicle for MDA. However, health care
workers described home visits as ‘‘very challenging’’ due to difficult
terrain, large coverage area, and financial constraints. Insufficient
drug supply was also a primary concern. One health worker
suggested that it would be ‘‘easier and better to give deworming
medicines only to those with symptoms and positive stool exams.’’
Due to their apprehensions about drug safety and feasibility,
healthcare workers requested ‘‘posters and advertisements’’ to
educate local people about drug safety as well as ‘‘training about
how to give deworming medicine’’ (Table 1).
Knowledge, Attitudes, and Practices Surveys
A total of 226 women of reproductive age responded to the
KAP survey with an average age of 29 years (Table 2). Forty-seven
percent of the women were married and 25% were employed
outside of the home. Forty-four percent of women completed high
school and 28% had private or government health insurance.
One-quarter of the women were pregnant and the average
number of previous pregnancies was 2.39. The average household
included 5 people and 2 rooms per home (Table 2).
The average score on all three knowledge scales was less than
50%. The mean Infection Score was 49.7% (15.965.64 out of 32),
the mean Treatment Score was 13.4% (2.1562.39 out of 16), and
the mean Birth Defect Score was 7.3% (0.5861.26 out of 8).
Women who were willing to take deworming medication while
pregnant had significantly higher Treatment Scores (mean rank
146.92 versus 103.1, z =24.40, p,0.001) and Birth Defect Scores
(mean rank 128.09 versus 108.65, z =22.43, p = 0.015) than
women unwilling to take STH medication during pregnancy. The
Infection Score was not correlated with willingness to take
deworming tablets while pregnant (Table 3).
Women of reproductive age who were willing to participate in a
government deworming program had significantly higher Infec-
tion Scores (mean rank 120.58 versus 99.79, z =22.27, p= 0.023)
and Treatment Scores (mean rank 124.32 versus 92.56, z =23.54,
p,0.001) than those women who refused to be a part of the
program (Table 4). Birth Defect Scores were not related to
willingness to participate. In summary, knowledge of treatment
and understanding of low teratogenic risk were associated with
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greater willingness to take deworming during pregnancy; mean-
while, knowledge of treatment and knowledge of infection were
related to greater willingness to participate in a government
deworming program.
The majority of women believed that STH treatment
commonly causes side effects (74.8%) as well as maternal harm
(67.3%) and fetal harm (77.9%). These perceptions were
associated with an unwillingness to take anthelminthic medications
during pregnancy (Table 5).
Discussion
Providers’ concerns were primarily founded in the lack of
evidence for drug safety during pregnancy. These fears may be
justified because although some evidence has shown deworming
decreases infections and anemia in pregnant women, further
human studies are needed to support the efficacy and safety of
these medications. According to the Federal Drug Administration
(FDA), albendazole and mebendazole are Category C drugs.
Animal studies have shown embryotoxic effects and skeletal
abnormalities in rats and rabbits [15]. A 1999 study of 7,087 Sri
Lankan pregnant women showed that mebendazole did not
increase the rate of birth defects [16]. In Israel, a 2003 prospective
cohort study of 284 women determined that gestational meben-
dazole treatment did not increase major anomalies, miscarriages,
stillbirths, or ectopic pregnancies [17]. Certain studies suggest that
anthelmintics in pregnancy increase the incidence of eczema, but
evidence remains unclear [8]. There is little research outside of
these results, and no studies have been conducted in the
Philippines. The WHO assumes that benefits of anthelmintics
outweigh the risk of fetal anomalies specificallywhen administered
in highly endemic regions after the first trimester.
Providers must first understand the safety of albendazole/
mebendazole before they will advocate for the implementation of
WHO guidelines. We recommend both disseminating evidence
and increasing local research initiatives. Educational initiatives
must target clinicians in endemic regions and emphasize correct
timing for medication administration. An important component of
developing an anthelminthic program for pregnant women will be
to track outcomes including the presence or lack of adverse fetal
effects.
In addition to uncertainty regarding drug safety, KIIs identified
inadequate healthcare infrastructure as another primary barrier to
STH treatment in pregnant women. FGDs with local health care
workers suggested deworming pregnant women is not a DOH
priority due to financial, workforce, and transportation constraints.
The KAP surveys reinforced the qualitative findings from the KIIs
and FGDs. The majority of local women believed STH treatment
during pregnancy would cause harm to themselves and their
babies.
A mass drug administration program relies on the knowledge
and acceptance of the targeted population. Fear of teratogenicity
among local women was primarily related to their lack of
knowledge about STH infections, treatment, and drug safety. In
a 2006 study in India, patient education significantly increased the
knowledge of Lymphatic Filariasis (LF) as well as MDA coverage
for LF in the targeted population [18]. Filipino women of
reproductive age would benefit from a similar educational
initiative.
It is important to note that there was inadequate knowledge
even among the survey population that was limited to women who
had access to medical care. Further studies could explore the
perspectives of women in rural communities who may prefer
traditional medicine or who may not seek health care.
As hypothesized, healthcare providers indicated that WHO
guidelines were not being followed on a local level. Fear of
teratogenicity among patients and providers was a major barrier.
Therefore, education must target providers as well. The KIIs and
FGDs were limited to providers at clinics with ongoing participa-
tion in a DOH deworming program. Health care workers from
clinics without familiarity with STH treatment would likely have
different perspectives.
In addition to fear of teratogenicity, LHUs lacked specific
protocols and drug supplies for the sustainable implementation of
WHO guidelines. Therefore, we also recommend incorporating
specific protocols for deworming pregnant women into DOH
guidelines, providing specific training for health workers, main-
taining drug supply, and monitoring program efficacy. Before
protocols can be implemented, however, addressing the fear of
teratogenicity among providers and patients is the imperative first
step to success in achieving optimal health outcomes for mothers
and infants in the Philippines.
Supporting Information
Appendix S1 Key Informant Interview Script. The script
was used during Key Informant Interviews with healthcare
providers including physicians and Department of Health officials.
(DOCX)
Appendix S2 Focus Group Discussion Script. The script
was used during Focus Group Discussions with healthcare
providers including nurses and barangay healthcare workers.
(DOCX)
Appendix S3 Knowledge, Attitudes, and Practices Sur-
vey. The survey was administered to women of reproductive age
in Cavite and Baguio City in the Philippines.
(DOCX)
Acknowledgments
June Rose Naig for assistance with translation and administrative
coordination. Andrew Plan for assistance with cultural competency,
navigation and data collection. Kristina Bacon for assistance with study
design and data analysis. Paul Chua for assistance with administrative
coordination.
Author Contributions
Conceived and designed the experiments: AJS ERI BJCM FIGT VYB.
Performed the experiments: AJS ERI. Analyzed the data: AJS ERI.
Contributed reagents/materials/analysis tools: AJS ERI FIGT BJCM
VYB. Wrote the paper: AJS ERI BJCM. Coordinated data collection sites:
VYB FIGT.
References
1. Hotez PJ, Bundy DAP, Beegle K, Brooker S, Drake L, et al. (2006) Helminth
infections: soil-transmitted helminth infection and schistosomiasis. In: Jamison
DT, Breman JG, Measham AR, Alleyne G, Claeson M, et al., editors. Ch 24.
Disease priority in developing countries. Washington: World Bank. pp. 467–78.
2. Brooker S, Bethony J, Hotez PJ (2004) Human hookworm infection in the 21st
century. Advances in Parasitology 58: 197–288.
3. WHO Expert Committee on the Control of Schistosomiasis (2001) Prevention
and control of schistosomiasis and soil-transmitted helminthiasis: report of a
WHO expert committee. WHO Technical Series Report 912.
4. Belizario VY, de Leon WU, Lumampao YF, Anastacio MB, Tai CM (2009)
Sentinel surveillance of soil-transmitted helminthiasis in selected local govern-
ment units in the Philippines. Asian Pacific Journal of Public Health 21(1): 26–
42.
Helminth Treatment Barriers during Pregnancy
PLOS ONE | www.plosone.org 6 February 2014 | Volume 9 | Issue 2 | e85992
5. Urbani C, Palmer K (2001) Drug-based helminth control in Western Pacific
countries: a general perspective. Tropical Medicine and International Health
6(11): 935–944.
6. Duque FT (2006) Integrated helminth control program. 2006.
7. Monse B, Naliponquit E, Belizario V, Benzian H, van Helderman WP (2010)
Essential health care package for children—the ‘Fit for School’ program in the
Philippines. International Dental Journal 60(2): 85–93.
8. Ndibazz J, Muhangi L, Akishule D, Kiggundu M, Ameke C, et al. (2010) Effects
of deworming during pregnancy on maternal and perinatal outcomes in
Entebbe, Uganda: a randomized controlled trial. Clinical Infectious Diseases 50:
531–540.
9. Torlesse H, Hodges M (2001) Albendazole therapy and reduced decline in
haemoglobin concentration during pregnancy. Transactions of the Royal
Society of Tropical Medicine and Hygiene 95: 195–201.
10. Larocque R, Casapia M, Gotuzzo E, MacLean JD, Soto JC, et al. (2006) A
double-blind randomized controlled trial of antenatal mebendazole to reduce
low birthweight in a hookworm-endemic area of Peru. Tropical Medicine and
International Health 11: 1485–1495.
11. Keiser J,Utzinger J (2008) Efficacy of current drugs against soil-transmitted
helminth infections: systematic review and meta-analysis. Journal of the
American Medical Association 299: 1937–1948.
12. Amarillo MLE, Belizario VY, Sadiang-ab JT, Sison SAM, Dayag AMS (2008)
Factors associated with the acceptance of mass drug administration for the
elimination of lymphatic filariasis in Agusan del Sur, Philippines. Parasites &
Vectors 1(1): 14.
13. Ona ET (2013) Department of health organizational chart. Republic of the
Philippines Department of Health. Available: http://www.doh.gov.ph/
organizational_chart.html. Accessed 5 January 2014.
14. Strauss A, Corbin J (1998) Basics of qualitative research 2nd ed. Thousand Oaks,
CA: SAGE publications. 378 p.
15. Christian MS (1987) Review of developmental toxicity (embryo-toxicity/
teratogenicity) and reproductive toxicity studies of albendazole in mice, rabbits,
and rats: unpublished report from Argus International. Submitted to WHO by
SmithKline and French.
16. de Silva NR, Srisena JLGJ, Dunasekera DPS, Ismail MM, de Silva HJ (1999)
Effect of mebendazole therapy during pregnancy on birth outcome. The Lancet
353(9159): 1145–1149.
17. Diav-Cirtin O, Shectman S, Arnon J, Lubart I, Ornoy A (2003) Pregnancy
outcome after gestational exposure to mebendazole: A prospective controlled
cohort study. Am J Obstet Gynecol 188: 282–285.
18. Nandha B, Krishnamoorthy K (2012) Impact of education campaign on
community-based vector control in hastening the process of elimination of
lymphatic filariasis in Tamil Nadu, South India. Health Educ Res 27: 585–94.
Helminth Treatment Barriers during Pregnancy
PLOS ONE | www.plosone.org 7 February 2014 | Volume 9 | Issue 2 | e85992
